Longevity Health Holdings Inc. (XAGE) Revenue History
Annual and quarterly revenue from 2021 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
XAGE Revenue Growth
XAGE Revenue Analysis (2021–2024)
As of May 8, 2026, Longevity Health Holdings Inc. (XAGE) generated trailing twelve-month (TTM) revenue of $1.5 million, reflecting explosive growth of +1975.5% year-over-year. The most recent quarter (Q3 2025) recorded $425,864 in revenue, down 15.4% sequentially.
Looking at the longer-term picture, XAGE's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $50,318 in 2024, representing a new all-time high.
When compared to Healthcare sector peers including HIMS (+59.0% YoY), MGRX (-38.2% YoY), and WELL (+38.3% YoY), XAGE has outperformed the peer group in terms of revenue growth. Compare XAGE vs HIMS →
XAGE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| XAGECurrent | $1M | +1975.5% | - | -9933.8% | |
 HIMS | $2.3B | +59.0% | +73.6% | 5.2% | |
 MGRX | $615,873 | -38.2% | - | -1294.4% | |
 WELL | $10.7B | +38.3% | +18.4% | 3.3% | |
 GDRX | $797M | -1.2% | +7.7% | 13.4% | |
 TALK | $229M | +22.0% | +24.6% | 1.4% |
XAGE Historical Revenue Data (2021–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $50K | - | $44K | 87.4% | $-4,998,498 | -9933.8% |
| 2023 | $0 | - | $-124,788 | - | $-5,217,280 | - |
| 2022 | $0 | - | $-242,556 | - | $-5,507,641 | - |
| 2021 | $0 | - | $0 | - | $-467,431 | - |
See XAGE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XAGE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XAGE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXAGE — Frequently Asked Questions
Quick answers to the most common questions about buying XAGE stock.
Is XAGE's revenue growth accelerating or slowing?
XAGE revenue is accelerating at +1975.5% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $1M. Growth momentum has increased versus prior periods.
What is XAGE's long-term revenue growth rate?
Longevity Health Holdings Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +1975.5% is above this long-term average.
How is XAGE's revenue distributed by segment?
XAGE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2021-2024 are available for download. Segment mix reveals concentration and diversification trends.